Skip to main content
Trillium Therapeutics Inc. logo

Trillium Therapeutics Inc. — Investor Relations & Filings

Ticker · TRIL ISIN · CA89620X5064 TSX Professional, scientific and technical activities
Open in API
Filings indexed 397 across all filing types
Latest filing 2021-11-26 Regulatory Filings
Country CA Canada
Listing TSX TRIL

About Trillium Therapeutics Inc.

http://www.trilliumtherapeutics.com

Trillium Therapeutics Inc. was a clinical-stage biopharmaceutical company specializing in immuno-oncology. The company focused on the discovery and development of innovative therapies for the treatment of cancer, particularly those targeting the immune system and its regulation. Trillium maintained preclinical programs and advanced several candidates through clinical trials in the oncology therapy area. In November 2021, Trillium Therapeutics was acquired by Pfizer Inc. and now operates as an integrated entity within Pfizer's global biopharmaceutical research and development structure, continuing its focus on advancing cancer treatments.

Recent filings

Filing Released Lang Actions
Notice.pdf
Regulatory Filings
2021-11-26 English
Other.pdf
Regulatory Filings
2021-11-17 English
News release - English.pdf
Regulatory Filings
2021-11-17 English
Other.pdf
Board/Management Information Classification · 100% confidence The document is a press release announcing a change in the company's board of directors, specifically the resignation of a board member and the appointment of an interim chairman of the Audit Committee. There is no financial data, no mention of a report or filing, and the content focuses solely on management/board changes. Therefore, it fits the category of Board/Management Information (MANG). The document length is short and it is not an announcement of a report publication or regulatory filing. Hence, the classification is MANG with high confidence.
2021-11-16 English
Other.pdf
M&A Activity Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC, which is used for reporting major events that shareholders should know about. The content describes a definitive arrangement agreement for Pfizer to acquire Trillium Therapeutics, including regulatory approvals and expected closing dates. It also mentions that Trillium's shares will cease trading upon completion of the arrangement. This is a clear announcement related to a merger/acquisition transaction. The document is not a full merger proxy statement or tender offer filing but an announcement of the transaction event. Therefore, the most appropriate classification is 'M&A Activity' (TAR), which covers announcements and documents related to merger proposals or takeover bids. The document length is under 5,000 characters, but it contains substantive event details, not just a report publication announcement. Hence, it is not RPA or RNS. Confidence is high due to explicit merger-related content and SEC Form 8-K context.
2021-11-16 English
Interim financial statements/report – English.pdf
Regulatory Filings
2021-11-12 English

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.